Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors.

[1]  J. Vessey,et al.  The Prevalence of Cardiac Valvular Insufficiency Assessed by Transthoracic Echocardiography in Obese Patients Treated with Appetitie-Suppressant Drugs , 1999 .

[2]  R. Rothman.  Does phentermine inhibit monoamine oxidase? , 1999, The Lancet.

[3]  R. Wurtman,et al.  Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines , 1999, The Lancet.

[4]  S. Erban,et al.  Risk for Valvular Heart Disease among Users of Fenfluramine and Dexfenfluramine Who Underwent Echocardiography before Use of Medication , 1998, Annals of Internal Medicine.

[5]  R. Wurtman,et al.  Effects of fenfluramine and phentermine (fen–phen) on dopamine and serotonin release in rat striatum: in vivo microdialysis study in conscious animals , 1998, Brain Research.

[6]  N. Weissman,et al.  An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. , 1998, The New England journal of medicine.

[7]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[8]  J. Vessey,et al.  The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. , 1998, The New England journal of medicine.

[9]  A. Balcioglu,et al.  Effects of phentermine on striatal dopamine and serotonin release in conscious rats:In vivo microdialysis study , 1998, International Journal of Obesity.

[10]  R. Rothman,et al.  Combined phentermine/fenfluramine administration and central serotonin neurons , 1998, Synapse.

[11]  M. C. Scorza,et al.  Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. , 1997, Biochemical pharmacology.

[12]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[13]  R. Wurtman,et al.  Neural control of dieting , 1996, Nature.

[14]  P. Riederer,et al.  The molecular pharmacology of L-deprenyl. , 1992, European journal of pharmacology.

[15]  L. Lasagna,et al.  Long‐term weight control study I (weeks 0 to 34) , 1992, Clinical pharmacology and therapeutics.

[16]  Yu Ph.  Inhibition of monoamine oxidase activity by phenylpropanolamine, an anorectic agent. , 1986 .

[17]  A. Mushlin,et al.  A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. , 1984, Archives of internal medicine.

[18]  H. Mehendale,et al.  Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. , 1983, The American review of respiratory disease.

[19]  B. Callingham,et al.  In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues. , 1982, Biochemical pharmacology.

[20]  C. N. Gillis,et al.  Indicator dilution measurement of 5-hydroxytryptamine clearance by human lung. , 1979, Journal of applied physiology: respiratory, environmental and exercise physiology.

[21]  D. Murphy,et al.  Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. , 1977, Biochemical pharmacology.

[22]  K. Tipton,et al.  Inhibition of monoamine oxidase by amphetamine and related compounds. , 1976, Biochemical pharmacology.

[23]  O. Wassermann,et al.  ON THE ROLE OF SEROTONIN IN THE PATHOGENESIS OF PULMONARY HYPERTENSION INDUCED BY ANORECTIC DRUGS; AN EXPERIMENTAL STUDY IN THE ISOLATED PERFUSED RAT LUNG II. FENFLURAMINE, MAZINDOL, MEFENOREX, PHENTERMINE AND R 800 , 1976, Clinical and experimental pharmacology & physiology.

[24]  A M Barrett,et al.  Inhibition of drug‐induced anorexia in rats by methysergide , 1975, The Journal of pharmacy and pharmacology.

[25]  O. Wassermann,et al.  MAO‐inhibitory properties of anorectic drugs , 1973, The Journal of pharmacy and pharmacology.

[26]  M. C. Trivedi,et al.  A determination of the anorexigenic potential of dl-amphetamine, d-amphetamine, l-amphetamine and phentermine. , 1969, Archives internationales de pharmacodynamie et de therapie.

[27]  N. Weissman.  Appetite suppressant valvulopathy : A review of current data , 1999 .

[28]  B. Corya,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[29]  U. Halbreich,et al.  The influence of estrogen on monoamine oxidase activity. , 1997, Psychopharmacology bulletin.

[30]  M. Worsham,et al.  Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[31]  P. Yu.  Inhibition of monoamine oxidase activity by phenylpropanolamine, an anorectic agent. , 1986, Research communications in chemical pathology and pharmacology.

[32]  R. Samanin.  Central mechanisms of anorectic drugs , 1981 .

[33]  R. Roth,et al.  Clearance of 5-hydroxytryptamine by rat lung and liver: the importance of relative perfusion and intrinsic clearance. , 1980, The Journal of pharmacology and experimental therapeutics.